Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
| Revenue (TTM) | 5,000 |
| Gross Profit (TTM) | $-1.36M |
| EBITDA | $-4.22M |
| Operating Margin | -30233.00% |
| Return on Equity | -198.10% |
| Return on Assets | -92.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.27 |
| Price-to-Book | 2.98 |
| Price-to-Sales (TTM) | 1298.92 |
| EV/Revenue | 1004.07 |
| EV/EBITDA | -3.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -25.00% |
| Shares Outstanding | $2.23M |
| Float | $1.85M |
| % Insiders | 4.10% |
| % Institutions | 5.97% |
Volatility is currently contracting